IQVIA Holdings Inc. (IQV) Fair Value & PE Analysis
Medical - Diagnostics & Research · NYSE
Current Price
$181.46
PE Ratio (TTM)
22.1x
Intrinsic Value
$225.99
+19.7% margin of safety
What Is IQVIA Holdings Inc.'s Fair Value?
As of 2026-06-12, applying a 22.0x earnings multiple to IQVIA Holdings Inc.'s (IQV) earnings per share of $8.22 yields a fair value estimate of $225.99 per share, versus a market price of $181.46.
Fair value from earnings multiples is sensitive to the multiple you choose. Across the sensitivity grid the estimate spans $184.73 to $273.14. This is a relative estimate anchored to earnings, not a statement of fact. For a cash flow based view, see the intrinsic value estimate on the DCF page.
How our PE model works · Recalculate in PE mode · IQV intrinsic value (DCF view)
Is IQVIA Holdings Inc. (IQV) Overvalued?
At $181.46, IQV trades about 19.7% below its PE-based fair value estimate, a modest discount to its earnings power, though not enough for us to call it cheap outright.
COMPETITIVE MOAT
↑Massive Data & Analytics Platform
IQVIA possesses an unparalleled, proprietary dataset of real-world evidence. This extensive data, combined with advanced analytics, creates a significant barrier to entry for competitors.
↑Deep Customer Relationships
Long-standing partnerships with pharmaceutical and biotech companies are crucial. These relationships are built on trust and the delivery of complex, integrated solutions.
↑AI-Driven Pharma Demand
The company's AI capabilities are increasingly sought after by the pharmaceutical industry. This demand fuels growth and strengthens its competitive position in a rapidly evolving market.
INVESTMENT RISKS
↓Intense Industry Competition
IQVIA faces competition from other CROs and technology providers like Veeva. Differentiation and innovation are critical to maintaining market share.
↓Regulatory Scrutiny & Data Privacy
The handling of sensitive health data exposes IQVIA to significant regulatory oversight and privacy concerns. Changes in regulations could impact operations.
↓Liquidity & Dividend Policy
Weak liquidity and the absence of a dividend may deter some investors. This could affect the stock's attractiveness and valuation.
Base case
IQV base case PE valuation
Intrinsic Value
$225.99
Margin of safety
+19.7%
Expected annual return
+4.5%
Base case assumptions: 10.4% annual earnings growth, 22x target PE, 10% discount rate, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the IQV PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for IQVIA Holdings Inc. respond.
Open PE Calculator for IQVCompany Overview
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Financial Metrics — IQV PE Stock Valuation Data
PE Ratio (TTM)
22.1x
PEG Ratio
2.27
Earnings Yield
4.53%
ROE (TTM)
22.5%
Revenue/Share (TTM)
$98.76
Debt/Equity
2.58x
Frequently Asked Questions
What is the PE ratio of IQV?
The trailing twelve-month PE ratio of IQV reflects how much investors pay per dollar of IQVIA Holdings Inc.'s earnings. This metric is most useful when compared to Medical - Diagnostics & Research peers and the company's own historical range.
Is IQV overvalued based on PE ratio?
IQV's PE of 22.1x combined with a PEG ratio of 2.27 provides a growth-adjusted perspective. A PEG above 2.0 suggests IQV may be richly valued even accounting for growth. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Diagnostics & Research, a DCF analysis may be more appropriate.
How do I value IQV stock using PE ratio?
To value IQVIA Holdings Inc. using PE: (1) Compare the current PE (22.1x) against the Medical - Diagnostics & Research median to assess relative pricing, (2) check the PEG ratio (2.27) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of IQV?
IQV's PEG ratio is 2.27, calculated by dividing the PE ratio (22.1x) by the expected earnings growth rate. A PEG above 2.0 often signals the stock is priced aggressively relative to its growth trajectory. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for IQV stock valuation?
PE ratio gives a quick relative read — how IQV is priced versus Medical - Diagnostics & Research peers. DCF provides an absolute value based on projected free cash flows. For IQV, with a strong ROE of 22.5%, both methods are worth using — PE for a market-relative check, DCF to stress-test whether fundamentals justify the price. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See IQV DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value IQV with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.